Why we invested in Isomorphic Labs, Demis Hassabis' AI-native drug discovery company
aleximm · x · 2026-11-17
The investor behind Isomorphic Labs explains the thesis: AI-powered drug discovery is one of AI's largest opportunities. Founded and chaired by Sir Demis Hassabis — who won the 2024 Nobel Prize in Chemistry for protein structure prediction — Isomorphic aims to build an AI-native pharmaceutical company with a mission to solve all disease. President Max Jaderberg, a prominent ML researcher and operator, rounds out a team the investor calls the decisive factor.
Related event: Isomorphic Labs Raises $5 Billion to Pursue AI-Driven Drug Discovery(13 posts)→
More from Venture
- Anthropic IPO filing reportedly reveals $900.9B in purchase and lease commitments through 2045 — Polymarket · 2026-11-17
- VC's 'Diffusion Gap' formula: lab revenue growth minus log-linear CapEx spend — saranormous · 2026-11-17
- Voyage Labs raises $12M for a specialized AI travel planning agent — TechCrunch AI · 2026-11-17
- HSBC dumps $300M of Oracle/OpenAI data center debt at steep mid-80s discount — GaryMarcus · 2026-11-17
- Isomorphic Labs raises $5B, its second mega-round in six months — The Decoder · 2026-11-17
- Isomorphic Labs closes $5B Series C to move drug candidates toward trials — TechCrunch AI · 2026-11-17